Nektar Therapeutics (NASDAQ:NKTR) has a beta value of 0.98 and has seen 1.21 million shares traded in the last trading session. The company, currently valued at $432.69M, closed the last trade at $25.01 per share which meant it lost -$0.09 on the day or -0.36% during that session. The NKTR stock price is -49.46% off its 52-week high price of $37.38 and 74.09% above the 52-week low of $6.48. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.14 million shares traded. The 3-month trading volume is 1.69 million shares.
The consensus among analysts is that Nektar Therapeutics (NKTR) is Buy stock at the moment, with a recommendation rating of 1.75. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -2.79.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Sporting -0.36% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NKTR stock price touched $25.01 or saw a rise of 4.87%. Year-to-date, Nektar Therapeutics shares have moved 35.56%, while the 5-day performance has seen it change 1.01%. Over the past 30 days, the shares of Nektar Therapeutics (NASDAQ:NKTR) have changed 120.35%. Short interest in the company has seen 0.6 million shares shorted with days to cover at 2.36.
Wall Street analysts have a consensus price target for the stock at $18.5, which means that the shares’ value could drop -35.19% from current levels. The projected low price target is $6.0 while the price target rests at a high of $24.0. In that case, then, we find that the current price level is 4.04% off the targeted high while a plunge would see the stock lose 76.01% from current levels.
Nektar Therapeutics (NKTR) estimates and forecasts
The company’s shares have gained 40.11% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -60.29%.
8 analysts offering their estimates for the company have set an average revenue estimate of 9.49M for the current quarter. 8 have an estimated revenue figure of 9.59M for the next ending quarter. Year-ago sales stood 23.49M and 24.12M respectively for this quarter and the next, and analysts expect sales will shrink by -59.60% for the current quarter and -60.29% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 25.49% over the past 5 years. Earnings growth for 2025 is a modest -33.49% while over the next 5 years, the company’s earnings are expected to decrease by -18.15%.
NKTR Dividends
Nektar Therapeutics is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Insiders own 1.29% of the company shares, while shares held by institutions stand at 67.11% with a share float percentage of 67.99%. Investors are also buoyed by the number of investors in a company, with Nektar Therapeutics having a total of 191.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 17.88 million shares worth more than $22.17 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 8.5599% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 15.16 million shares as of 2024-06-30. The firm’s total holdings are worth over $18.79 million and represent 7.2575% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 3.57% shares in the company for having 443.34 shares of worth $11.09 million while later fund manager owns 381.65 shares of worth $9.55 million as of Mar 31, 2025 , which makes it owner of about 3.08% of company’s outstanding stock.
